# A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

> **NCT06723535** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 27 (actual)

## Conditions studied

- Kidney Failure, Chronic
- Healthy Volunteers
- Renal Impairment

## Interventions

- **DRUG:** BMS-986278

## Key facts

- **NCT ID:** NCT06723535
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-07
- **Primary completion:** 2025-09-16
- **Final completion:** 2025-09-19
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723535, "A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06723535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*